Chronic Lymphocytic Leukemia | Clinical

Ibrutinib Extends PFS in Patients with TP53-Mutated Chronic Lymphocytic Leukemia

March 30, 2021

In an interview with Targeted Oncology, John N. Allan, MD, a hematology oncologist at Weill Cornell Medicine, discussed how ibrutinib extends PFS in patients with CLL. He also discussed combination therapy in the future of CLL treatment.

Clinical Benefit Demonstrated With Ublituximab Plus Ibrutinib in R/R CLL

March 15, 2021

Patients with relapsed or refractory high-risk chronic lymphocytic leukemia achieved a statistically higher rate of overall response when the glycoengineered, type I anti-CD20 monoclonal antibody ublituximab was added to the Bruton’s tyrosine kinase inhibitor ibrutinib, according to results from the phase 3 GENUINE study.

Evidence Supports BTK Inhibition in Chronic Lymphocytic Leukemia

January 28, 2021

The role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia is supported by clinical trial research. During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Peter Hillmen, MB ChB, PhD, provided evidence around acalabrutinib for the case of a 61-year-old woman.

Progression-Free Survival With Acalabrutinib Non-Inferior to Ibrutinib in High-Risk CLL

January 26, 2021

In adults with previously treated, high-risk chronic lymphocytic leukemia, treatment with acalabrutinib was found to be non-inferior to treatment with ibrutinib in terms of progression-free survival, meeting the primary end point of the phase 3 ELEVATE-RR clinical trial.